Wilson Julian B, Hoang Thanh D, Lee Martin L, Epstein Ma'ayan, Friedman Theodore C
Division of Endocrinology, Metabolism and Molecular Medicine, Department of Internal Medicine, Charles R. Drew University of Medicine and Science, Los Angeles, California, United States of America.
Endocrinology Division, Walter Reed National Military Medical Center, Bethesda, Maryland, United States of America.
PLoS One. 2025 Jun 9;20(6):e0325046. doi: 10.1371/journal.pone.0325046. eCollection 2025.
Reverse T3 (rT3) is a biologically inactive form of T3 (triiodothyronine), a thyroid hormone, that is created by peripheral 5 deiodination of T4 (thyroxine) by type 1 and type 3 deiodinase enzymes (D1 and D3 respectively) and may block T3 binding to the thyroid hormone receptor. Approximately 15% of patients on L-T4 replacement therapy with a normalized thyroid-stimulating hormone (TSH) report experience continued fatigue and other hypothyroid symptoms; therefore, efforts are needed to understand why this occurs and how it can be corrected. Decades ago, endocrinologists realized that in patients with severe illnesses, rT3 is typically high and T3 is typically low; this was termed "euthyroid sick syndrome". More recently, functional medicine and other doctors, have argued that high rT3 is detrimental and can block T3 from binding to the thyroid hormone receptor. Due to the lack of peer-reviewed publications on this topic, functional medicine doctors continue to rely heavily on rT3 levels to treat patients that may have no other laboratory findings of hypothyroidism and often prescribe L-T3-only preparations to patients in an effort to lower rT3.
The initial rT3 measurements done by liquid chromatography/tandem mass spectrometry (LC/MS-MS) were retrospectively analyzed from the initial blood tests in 976 consecutive patients, with symptoms of fatigue and treated for hypothyroidism, in a private Endocrinology practice. TSH, free T3 and free T4 were measured by electrochemiluminescence immunoassay (ECLIA). The upper limit of normal rT3 (24.1 ng/dL) was used as a cut-off for results above the normal range.
The number of patients with rT3 levels above normal range varied significantly with the type of thyroid hormone replacement prescribed. The highest rate of an elevated rT3 was 20.9% (29/139) in patients taking T4 alone. Nine% (31/345) of patients not taking thyroid hormone replacement had elevated rT3. Patients on all types of L-T4 treatment had higher rT3 levels than those not on L-T4 treatment (p < 0.00001) and they also had a higher percentage of rT3 levels above the cutoff of 24.1 ng/dL (p < 0.00001). Linear regression analysis showed rT3 levels correlated with free T4 and free T3 levels and inversely with log TSH levels.
This study found elevated rT3 levels in patients with symptoms of fatigue on various thyroid hormone replacements with the highest levels of rT3 in those taking L-T4 replacement alone and the lowest levels of rT3 in those on preparations that contained L-T3 alone.
反式三碘甲状腺原氨酸(rT3)是甲状腺激素三碘甲状腺原氨酸(T3)的一种无生物活性形式,它由1型和3型脱碘酶(分别为D1和D3)对甲状腺素(T4)进行外周5位脱碘作用产生,可能会阻断T3与甲状腺激素受体的结合。在促甲状腺激素(TSH)水平正常的左甲状腺素(L-T4)替代治疗患者中,约15%报告仍有持续疲劳和其他甲状腺功能减退症状;因此,需要努力了解其发生原因及如何纠正。几十年前,内分泌学家就已认识到,在重症患者中,rT3通常较高而T3通常较低;这被称为“正常甲状腺病态综合征”。最近,功能医学医生及其他医生认为,高rT3有害,会阻断T3与甲状腺激素受体的结合。由于缺乏关于该主题的同行评审出版物,功能医学医生在治疗可能无其他甲状腺功能减退实验室检查结果的患者时,仍严重依赖rT3水平,且常给患者开仅含L-T3的制剂以降低rT3。
对一家私人内分泌诊所976例连续的有疲劳症状且接受甲状腺功能减退治疗的患者进行回顾性分析,这些患者最初的血液检测采用液相色谱/串联质谱法(LC/MS-MS)测定rT3。采用电化学发光免疫分析法(ECLIA)测定TSH、游离T3和游离T4。正常rT3的上限(24.1 ng/dL)用作高于正常范围结果的临界值。
rT3水平高于正常范围的患者数量因所开甲状腺激素替代类型的不同而有显著差异。仅服用T4的患者中rT3升高率最高,为20.9%(29/139)。未接受甲状腺激素替代治疗的患者中有9%(31/345)rT3升高。接受所有类型L-T4治疗的患者rT3水平高于未接受L-T4治疗的患者(p<0.00001),且其rT3水平高于24.1 ng/dL临界值的百分比也更高(p<0.00001)。线性回归分析显示,rT3水平与游离T4和游离T3水平相关,与log TSH水平呈负相关。
本研究发现,有疲劳症状的患者在接受各种甲状腺激素替代治疗时rT3水平升高,其中仅接受L-T4替代治疗的患者rT3水平最高,仅接受含L-T3制剂治疗的患者rT3水平最低。